We look back at some of 2025’s major advances in AI-driven live cell analytics, from automated mitochondrial segmentation to dynamic EC50 profiling and next-generation T-cell insights. These breakthroughs bring deeper, label-free understanding to drug discovery and immuno-oncology.
Nanolive hosted this event on “CAR T cells live and up-close: Metabolic engineering for enhanced function.” In this webinar, presented by Dr Roddy O’Connor, Research Assistant Professor at University of Pennsylvania’s renowned Center for Cellular...
With animal-testing bans in place, cosmetics R&D urgently needs reliable in vitro models that combine predictive power, reproducibility, and ethical compliance. Nanolive’s CRO services provide label-free, high-content live-cell analysis to assess ingredient safety, toxicity, and efficacy…
Phenotypic screening has re-emerged as a powerful approach for identifying and characterizing drug candidates, especially in an era where mechanism-based screening often overlooks complex biological responses…
Drug selectivity is essential for maximizing therapeutic efficacy while minimizing toxicity to healthy cells, a key driver of clinical success. Measuring drug effects on target cells alone often overlooks off-target toxicity that can deprioritize promising candidates…
